Pricing Log in Create free account

Enanta Pharmaceuticals, Inc. (ENTA) vs Scribe Therapeutics Inc. (SCTX)

Enanta Pharmaceuticals, Inc. and Scribe Therapeutics Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and Scribe Therapeutics Inc. are of similar size ($293.6M and $293.1M). Across the 3 metrics below, Scribe Therapeutics Inc. leads on 2 and Enanta Pharmaceuticals, Inc. on 1.

Valuation

Metric ENTA SCTX Biotechnology median
P/E n/m — 10.60
P/S 4.90 n/m 9.40
P/B 3.17 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 2.00 n/m 9.02
Earnings yield (21.91%) — (32.88%)
Free cash flow yield (11.54%) 0.00% (23.13%)

Profitability

Metric ENTA SCTX Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (89.99%) — 0.00%
Net margin (96.89%) — 0.00%
Free cash flow margin (56.60%) — 0.00%
Return on equity (70.12%) — (51.96%)
Return on assets (21.15%) — (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENTA SCTX Biotechnology median
Revenue growth (TTM) 0.70% — 6.76%
EPS growth (last fiscal year) 29.93% — 29.88%
Revenue growth, 5-year CAGR (11.81%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ENTA SCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.76 0.57 4.97
Net debt to EBITDA 2.35 0.00 1.01

Dividend

Metric ENTA SCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENTA SCTX Biotechnology median
Market cap 293.59m 293.06m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack